News >

Carboplatin/Cabazitaxel Combo Shows PFS Benefit in mCRPC

Lisa Astor
Published: Tuesday, Sep 17, 2019

Paul G. Corn, MD, PhD

Paul G. Corn, MD, PhD

The combination of cabazitaxel (Jevtana) in combination with carboplatin demonstrated an improvement in progression-free survival (PFS) versus cabazitaxel alone in men with metastatic castration-resistant prostate cancer (mCRPC), according to findings of a phase I/II trial published in Lancet Oncology.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x